Latanoprost 0.005%

DRUG15 trials

Sponsors

Yale University, Pharmaceutical Research Network, Pfizer, Bausch & Lomb Incorporated, Allergan

Conditions

GlaucomaGlaucoma, Open-AngleGlaucoma, Open-angleHypertension, OcularOcular HypertensionOcular Hypertension (OHT)Open Angle GlaucomaOpen-Angle Glaucoma

Phase 1

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

CompletedNCT03293992

Hoffmann-La RocheGlaucoma, Open-angle, Ocular Hypertension

Start: 2017-10-10End: 2017-12-21Updated: 2020-03-31

Phase 2

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

CompletedNCT00572455

PfizerOcular Hypertension, Primary Open-Angle Glaucoma

Start: 2007-12-11End: 2009-06-26Updated: 2021-04-30

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

CompletedNCT00595101

Bausch & Lomb IncorporatedOcular Hypertension, Primary Open Angle Glaucoma

Start: 2007-12-31End: 2008-06-30Updated: 2020-09-14

AR-12286 in Combination With Latanoprost

CompletedNCT01302249

Aerie PharmaceuticalsGlaucoma, Ocular Hypertension

Start: 2011-02-28End: 2011-12-31Updated: 2014-05-08

AL-54478 Proof of Concept Study

CompletedNCT01318252

Alcon ResearchOcular Hypertension (OHT), Open-angle Glaucoma (OAG)

Start: 2011-06-30End: 2011-10-31Updated: 2014-07-31

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

CompletedNCT03657797

Nicox Ophthalmics, Inc.Glaucoma, Open-Angle, Hypertension, Ocular

Start: 2018-08-01End: 2019-08-23Updated: 2023-06-18

Phase 3

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

CompletedNCT00800267

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Glaucoma, Ocular Hypertension

Start: 1997-07-31End: 1999-06-30Updated: 2021-02-18

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

CompletedNCT04630808

Nicox Ophthalmics, Inc.Ocular Hypertension, Open Angle Glaucoma

Start: 2020-11-09End: 2025-06-25Updated: 2025-09-08

Phase 4

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

CompletedNCT00224289

Yale UniversityGlaucoma

Start: 2005-03-31End: 2009-04-30Updated: 2012-12-10

Cosopt Versus Xalatan

CompletedNCT00273429

Pharmaceutical Research NetworkOcular Hypertension, Open-Angle Glaucoma

Start: 2005-04-30End: 2005-12-31Updated: 2007-01-09

Latanoprost Versus Fotil

CompletedNCT00304785

Pharmaceutical Research NetworkOcular Hypertension, Open-Angle Glaucoma

Start: 2005-05-31End: 2007-10-31Target: 36Updated: 2007-10-24

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

CompletedNCT00735449

AllerganGlaucoma, Ocular Hypertension

Start: 2008-07-31End: 2009-12-31Updated: 2019-04-23

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

CompletedNCT00811564

AllerganGlaucoma, Ocular Hypertension

Start: 2008-12-31End: 2010-01-31Updated: 2011-09-21

Nailfold Capillary Blood Flow With Latanoprost Bunod

CompletedNCT03949244

Icahn School of Medicine at Mount SinaiGlaucoma, Open-Angle

Start: 2019-08-15End: 2020-10-01Updated: 2021-09-29

Unknown Phase

Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

CompletedNCT01042665

University of MiamiGlaucoma

Start: 2006-02-28End: 2009-12-31Updated: 2014-03-28

Related Papers

A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.

2011-09-0138 citations